Journal
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
Volume 196, Issue 2, Pages 97-106Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.ajog.2006.05.056
Keywords
menopause; selective serotonin reuptake inhibitor; serotonin-norepinephrine reuptake inhibitor; vasomotor symptoms
Categories
Ask authors/readers for more resources
OBJECTIVE: The decline in concentrations of gonadal hormones during menopause gives rise to a range of physiologic and psychologic changes that may impact a woman's health and quality of life significantly. Most notable among these are vasomotor symptoms (hot flashes and night sweats) and mood and sleep disturbances. STUDY DESIGN: This article reviews the physiologic condition underlying menopausal vasomotor symptoms and centrally active, nonhormonal therapies that have demonstrated efficacy for their treatment. RESULTS: Despite the emergence of a range of nonhormonal treatments for vasomotor symptoms, a need still exists for safe and effective therapeutic options that directly target the underlying thermoregulatory mechanisms for women who want treatment but prefer to avoid hormone therapy or for whom hormone therapy is contraindicated. CONCLUSION: The availability of centrally active therapies for menopausal vasomotor symptoms with risks and benefits clearly defined by results from well-designed clinical trials has the potential to allay safety concerns that are associated with the treatment of these common symptoms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available